Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Overview
Nevro Corp (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California. The company is renowned for its innovative approach in the field of neuromodulation and chronic pain management, providing advanced spinal cord stimulation (SCS) systems designed to transform patient outcomes. Nevro specializes in the development and commercialization of its flagship Senza SCS system, which uniquely delivers its proprietary 10 kHz high-frequency therapy. This evidence-based treatment is implemented through a comprehensive, integrated platform aimed at alleviating chronic pain across multiple conditions.
Technology and Innovation
Nevro’s technology centers on generating electrical impulses that modulate pain signals. The Senza system, along with the broader HFX platform, is built on groundbreaking research and clinical evidence. Its design incorporates sophisticated programming and, more recently, artificial intelligence enhancements through HFX AdaptivAI. This AI-driven component harnesses big data, precise algorithms, and extensive clinical outcomes to offer personalized, real-time pain relief. As a result, patients are empowered to control their pain management in a manner that is tailored to their individual needs, reducing reliance on generalized treatments.
Product Portfolio and Market Position
The company has established a diversified portfolio that not only focuses on conventional SCS devices but also extends into minimally invasive treatments for sacroiliac (SI) joint pain and fusion procedures. By broadening its offerings, Nevro addresses various facets of chronic pain, including back pain, painful diabetic neuropathy, and SI joint dysfunction. This strategic diversification enables Nevro to maintain a unique competitive edge in a market characterized by substantial underpenetration and evolving treatment protocols.
Patient and Physician Support
An integral part of Nevro’s approach lies in its comprehensive support services. The company provides extensive educational resources and application support via programs like HFX Coach, designed to ensure that patients receive continuous guidance throughout their therapy journey. Alongside patient-centric initiatives, Nevro offers advanced, cloud-based insights for physicians, empowering them with real-time data to optimize treatment plans and enhance overall practice management.
Global Reach and Regulatory Milestones
Nevro’s neuromodulation solutions are commercially available in major markets such as the United States, Europe, and Australia. Over the years, the company has successfully achieved key regulatory approvals, including CE Mark and FDA clearance, which attest to the safety, efficacy, and scientific rigor underlying its products. These milestones have not only reinforced Nevro’s position in the global medical device arena but have also paved the way for further market penetration and adoption of its innovative therapies.
Competitive Landscape and Differentiators
Operating in a highly competitive healthcare sector, Nevro differentiates itself through an unwavering commitment to evidence-based medicine and technological innovation. Its products are developed with the dual aim of delivering consistent pain relief while also ensuring a high quality of life for patients. The use of advanced AI, coupled with extensive clinical validation, positions Nevro as an authoritative entity in chronic pain treatment options. This unique amalgamation of rigorous clinical research, technological sophistication, and robust support services sets Nevro apart from its peers in the neuromodulation industry.
Conclusion
Nevro Corp remains dedicated to advancing chronic pain management through its cutting-edge medical devices and holistic care solutions. With a focus on developing technologies that are not only innovative but also grounded in robust clinical evidence, Nevro continues to enhance patient outcomes and redefine approaches to pain management across global markets.
Nevro Corp. (NVRO) reported Q1 2021 revenue of $88.6 million, a 1% increase from the prior year. The net loss from operations was $22.5 million, with non-GAAP adjusted EBITDA of negative $6.6 million. The company updated its full-year revenue guidance to $440 million to $450 million, reflecting anticipated growth of 22% to 24% compared to 2020. Notable advancements include FDA approval for the Omnia upgrade and positive clinical trial results published in JAMA Neurology, indicating improved outcomes for patients.
Nevro Corp. (NYSE: NVRO), a leading medical device company specializing in chronic pain solutions, announced that its Chairman and CEO, D. Keith Grossman, will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 4:00 pm ET. The event will be accessible via a live webcast and archived recording on Nevro's website.
Nevro is known for its innovative Senza spinal cord stimulation system, which has shown positive outcomes, including opioid reduction in over 65% of patients in clinical studies. For more information, visit www.nevro.com.
Nevro Corp. (NYSE: NVRO) has launched its new HFX brand and updated website aimed at enhancing the experience for physicians and patients in chronic pain treatment. The HFX brand consolidates Nevro's offerings, including the U.S. launch of the Omnia upgrade powered by HFX Connect, which facilitates remote therapy optimization through dedicated HFX Coaches. This system leverages data from over 70,000 patient outcomes and includes features like remote diagnostics and real-time patient care tracking. The company anticipates expanding its HFX Connect upgrade to Australia and Europe shortly.
Nevro Corp. announced the appointment of Jon Shear as the new Vice President of Corporate Development, effective immediately. Shear, who has extensive experience in the medical technologies sector, will lead Nevro's strategic planning and business development initiatives. He previously founded Westward Medtech and held significant roles at Thoratec Corporation and St. Jude Medical. This leadership change may enhance Nevro's strategic alignment and long-term growth trajectory, critical for improving shareholder value.
On April 13, 2021, Nevro Corp. (NYSE: NVRO), a leader in innovative solutions for chronic pain treatment, announced that Keith Grossman, Chairman and CEO, will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 2:00 PM ET. A live webcast will be available on Nevro's website, alongside archived recordings for investors. Nevro is renowned for its Senza spinal cord stimulation systems, which utilize HF10 therapy to significantly reduce opioid dependency in patients.
Nevro Corp. (NYSE: NVRO) will report its financial results for Q1 2021 after the market closes on May 5, 2021. A conference call is scheduled for the same day at 1:30 PM PT to discuss the results. Investors can join the call by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally. Nevro focuses on innovative solutions for chronic pain, with its Senza spinal cord stimulation system showing the potential to reduce opioid use in over 65% of patients. For more information, visit www.nevro.com.
Nevro Corp. (NYSE: NVRO) announced the publication of the SENZA-PDN clinical trial results in JAMA Neurology. This trial evaluated the use of the Senza® System for treating chronic pain associated with Painful Diabetic Neuropathy (PDN), potentially becoming the first FDA-approved spinal cord stimulation (SCS) system specifically for PDN. The trial showed significant pain relief for 85% of patients using high-frequency (10 kHz) SCS compared to 5% in the control group. The FDA review is expected to take six months, with a potential launch planned for the second half of 2021.
Nevro Corp. (NYSE: NVRO) reported a fourth quarter 2020 revenue of $109.7 million, down 4% year-over-year, with a net loss from operations of $0.9 million. Worldwide revenue for 2020 reached $362.0 million, a 7% decrease from 2019. For 2021, the company expects revenue of $430 million to $450 million amid ongoing COVID-19 related challenges and plans to launch treatments for Painful Diabetic Neuropathy. Despite obstacles, Nevro anticipates a return to growth as pandemic conditions improve and elective procedures resume.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, announced that D. Keith Grossman, Chairman and CEO, will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 10:40 AM ET. A live webcast and archived recording of the presentation will be available on Nevro's website. The company is known for its innovative Senza spinal cord stimulation system, which has shown efficacy in reducing opioid dependency in chronic pain patients.
Nevro Corp. (NYSE: NVRO) announced that D. Keith Grossman, Chairman and CEO, will present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on February 25, 2021, at 1:30 PM ET / 10:30 AM PT. The event will be accessible via a live webcast on Nevro's website, where an archived recording will also be available.
Nevro, based in Redwood City, California, specializes in innovative solutions for chronic pain treatment, particularly through its proprietary HF10 therapy, proven to reduce or eliminate opioids in over 65% of patients.
FAQ
What is the current stock price of Nevro (NVRO)?
What is the market cap of Nevro (NVRO)?
What is Nevro Corp's primary business?
Which products form the core of Nevro's portfolio?
How does Nevro's spinal cord stimulation system work?
In which markets are Nevro's products available?
What role does technology play in Nevro's treatments?
How does Nevro support its patients and healthcare providers?
What differentiates Nevro from other pain management companies?
What conditions do Nevro's therapies target?
